Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds

Author(s): Mohammad Bayat, Abdollah Amini, Fatemesadat Rezaie, Shiva Bayat

Journal Name: Recent Patents on Regenerative Medicine
Continued as Current Regenerative Medicine

Volume 4 , Issue 2 , 2014


Each year in the United States alone, for about 50 million surgeries is undertaken. An extra 50 million traumatic wounds increased further the burden of morbidity stemming from acute wounds. For instance, chronic ulcers are a growing cause of significant patient morbidity and mortality. Pentoxifylline, a xanthine derivative, is a non-selective phosphodiesterase inhibitor that raises intracellular cyclic adenosine monophosphate. Pentoxifylline has been used clinically to treat vascular diseases and some types of chronic wounds. The purpose of this paper is to provide an overview on all available patents regarding pentoxifylline administration for abnormal wound healing and chronic wounds. All available published patents regarding to effect of pentoxifylline on abnormal wound healing and ulcers were studied. These patents reveal that pentoxifylline administration has an important additional effect in the treatment of different diseases such as fibrosis, Peyronie’s disease, venous leg ulcers, circulatory disorders, vascular occlusive wounds and diabetic ulcer wounds.

Keywords: Pentoxifylline, peyronie’s disease, ulcer, vascular occlusive disease, wound, wound healing.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [137 - 143]
Pages: 7
DOI: 10.2174/2210296504666140813194744
Price: $65

Article Metrics

PDF: 11